Hikma Pharmaceuticals (HIK LN)

Analysis

Health Care • United Kingdom

Hikma Pharmaceuticals develops, manufactures, and markets a broad range of generic, branded, and in-licensed pharmaceutical products across North America, the Middle East and North Africa (MENA), and Europe. The company specializes in injectables, branded generics, and other non-injectable generic and specialty products for hospitals and retail markets. Hikma Pharmaceuticals was founded in 1978 in Amman, Jordan, and is headquartered in London, UK.

Refresh

Exchange Announcement • 24 Sep 2026 13:00

Hikma appoints Rebecca Hall as CFO

Exchange Announcement • 22 Sep 2026 18:00

Hikma R&D Investor Spotlight Series

Exchange Announcement • 22 Sep 2026 15:32

Director/PDMR Shareholding

Exchange Announcement • 02 Sep 2026 19:45

Holding(s) in Company

Exchange Announcement • 01 Sep 2026 22:13

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hikma appoints Rebecca Hall as CFO

Hikma R&D Investor Spotlight Series

Director/PDMR Shareholding

Holding(s) in Company

Total Voting Rights